Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.04 a new company low.

Within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Trinity Biotech Plc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 3625 to 4298.

Explain Quick Ratio?
How much Cash & cash equivalents TRIB�s has?
What are TRIB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TRIB/financial-strength

https://api.csimarket.com/api/v1/companies/TRIB/fundamentals

https://api.csimarket.com/api/v1/companies/TRIB/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

TRIB Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	260.8 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-1.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.04	Subscribe	Subscribe	Subscribe	Subscribe
TRIB's Total Ranking	# 4298	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 888
Overall Market	# 4298

Quick Ratio Statistics
High	Average	Low
0.49	0.29	0.04
(Dec 31 2022)		(Dec 31 2025)

Financial Statements
Trinity Biotech Plc's Current Liabilities	$ 141 Millions	Visit TRIB's Balance sheet
Trinity Biotech Plc's Cash & cash equivalent	$ 6 Millions	Visit TRIB's Balance sheet
Source of TRIB's Sales		Visit TRIB's Sales by Geography

Cumulative Trinity Biotech Plc's Quick Ratio

TRIB's Quick Ratio for the trailling 12 Months

TRIB Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	324.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-1.04 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.04	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3150	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	22.06 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-0.41 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to TRIB Financial Strength Comparisons >> Go to Compare TRIB Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $141.21 millions, cumulative Quick Ratio decreased to 0.04 below the Trinity Biotech Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 13 other companies have achieved higher Quick Ratio than Trinity Biotech Plc. While Quick Ratio overall ranking has improved so far to 3150, from total ranking during the twelve months ending third quarter 2025 at 3748.

Explain Quick Ratio?
How much Cash & cash equivalents TRIB�s has?
What are TRIB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 14
Healthcare Sector	# 807
Within the Market	# 3150

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.49	0.33	0.21
(Dec 31 2022)		(Mar 31 2020)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Trinity Biotech Plc	0.04	$ 5.594 Millions	$ 141.209 Millions
Burzynski Research Institute Inc	0.03	$ 0.002 Millions	$ 0.070 Millions

Date modified: 2026-07-07T13:58:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.